Menopausal hormone therapy and melanoma risk in the Australian longitudinal study on women's health
File version
Version of Record (VoR)
Author(s)
Xu, Zhiwei
Stoer, Nathalie C
Mishra, Gita D
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
Abstract
New evidence on the association between use of menopausal hormone therapy and increased risk of cutaneous melanoma (CM) is emerging. In the Australian Longitudinal Study on Women's Health, we followed 18,850 postmenopausal women for a median of 13.2 years, and observed 356 incident CMs. We found an indication of an association between use of unopposed oestrogen therapy and CM risk (hazard ratio (HR) 1.26; 95% confidence interval (CI) 0.98, 1.61), and no association between use of oestrogen-progestin therapy and CM risk (HR 0.99; 95% CI 0.37, 2.67). More studies are needed to elucidate the potential impact of different types of hormone therapy on CM risk.
Journal Title
Maturitas
Conference Title
Book Title
Edition
Volume
160
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
Item Access Status
Note
Access the data
Related item(s)
Subject
Biomedical and clinical sciences
Health sciences
Science & Technology
Life Sciences & Biomedicine
Geriatrics & Gerontology
Obstetrics & Gynecology
Melanoma
Persistent link to this record
Citation
Botteri, E; Xu, Z; Stoer, NC; Mishra, GD, Menopausal hormone therapy and melanoma risk in the Australian longitudinal study on women's health, Maturitas, 2022, 160, pp. 1-3